ArticleJournal of molecular histology2025
EIF4A3-Mediated downregulation of circPTEN promotes hepatocellular carcinoma progression through the miR-1289/RBM38 Axis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide. Our research endeavored to delineate the role of circPTEN and to assess its potential as a prognostic biomarker in HCC. CircPTEN expression was quantified in HCC cells and clinical specimens using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The effects of circPTEN overexpression on cellular activities were evaluated through Cell Counting Kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EDU), and Transwell assays. The impact of circPTEN overexpression on HCC tumorigenesis and metastasis was also assessed in xenograft mouse models. Kaplan-Meier survival analysis was conducted to assess circPTEN's prognostic value, while additional experiments were conducted to examine the circPTEN-microRNA-1289 (miR-1289) interaction and Eukaryotic Initiation Factor 4A3 (EIF4A3) regulatory effect on circPTEN expression. Our investigations revealed significantly reduced circPTEN expression in HCC, with lower levels correlating with poorer patient outcomes. In vitro experiments demonstrated that enhancing circPTEN expression could inhibit both the proliferation and invasiveness of HCC cells. At the molecular level, circPTEN functioned as a microRNA sponge for miR-1289, consequently upregulating RNA Binding Motif Protein 38 (RBM38), a validated tumor suppressor in HCC. Furthermore, EIF4A3 was identified as a negative regulator of circPTEN expression in HCC cells. Nude mouse model experiments corroborated our in vitro results, showing that increased circPTEN expression corresponded with reduced tumorigenesis and metastatic spread. CircPTEN functions as a tumor suppressor in HCC, regulating the miR-1289/RBM38 axis while being negatively regulated by EIF4A3. Restoration of circPTEN expression represents a potential therapeutic strategy for HCC, and circPTEN levels may serve as a candidate prognostic biomarker.
Indexed as
Identifiers
40527976What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.